Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Caption Management LLC

Caption Management LLC trimmed its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 82.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,998 shares of the company's stock after selling 95,674 shares during the period. Caption Management LLC's holdings in Ginkgo Bioworks were worth $196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. FNY Investment Advisers LLC boosted its stake in shares of Ginkgo Bioworks by 125.6% during the fourth quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company's stock valued at $745,000 after purchasing an additional 42,298 shares in the last quarter. SG Americas Securities LLC bought a new stake in Ginkgo Bioworks during the 4th quarter valued at $199,000. KBC Group NV purchased a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $31,000. Forbes J M & Co. LLP raised its position in shares of Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after acquiring an additional 576,732 shares in the last quarter. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Ginkgo Bioworks during the 4th quarter worth $144,000. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Stock Performance

DNA stock traded down $0.30 during trading on Tuesday, reaching $8.01. 520,316 shares of the company traded hands, compared to its average volume of 1,468,495. The business has a 50 day simple moving average of $7.13 and a 200 day simple moving average of $9.08. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $38.58. The company has a market capitalization of $464.85 million, a price-to-earnings ratio of -0.61 and a beta of 1.29.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The firm had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. As a group, research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.